NASDAQ:NTRP Neurotrope (NTRP) Stock Price, News & Analysis → Democrats’ “break glass for emergency” candidate for 2024 (From The Freeport Society) (Ad) Free NTRP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.79▼$1.9350-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume1,586 shsAverage Volume7,881 shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsTrendsStock AnalysisCompetitorsEarningsTrends Get Neurotrope alerts: Email Address Ad The Freeport SocietyDemocrats’ “break glass for emergency” candidate for 2024Nate Silver has been a celebrity pundit since at least the 2008 election, when he correctly predicted the winner in 49 of 50 states, and nailed all 35 Senate election outcomes. But interestingly, one man reached the same conclusion as Nate Silver a long time ago…For full details, click here. About Neurotrope Stock (NASDAQ:NTRP)Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More Ad The Freeport SocietyDemocrats’ “break glass for emergency” candidate for 2024Nate Silver has been a celebrity pundit since at least the 2008 election, when he correctly predicted the winner in 49 of 50 states, and nailed all 35 Senate election outcomes. But interestingly, one man reached the same conclusion as Nate Silver a long time ago…For full details, click here. NTRP Stock News HeadlinesMay 18, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Stock Price, News, Quote & History - Yahoo FinanceApril 30, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Latest Stock News & Headlines - Yahoo FinanceApril 4, 2024 | morningstar.comNextTrip Inc NTRPAugust 17, 2023 | finance.yahoo.comAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightJune 22, 2022 | finance.yahoo.comAt 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceApril 7, 2022 | prnewswire.comVascular Dementia Market Is Contemplated to Surge at a CAGR of 4.05% in the 7MM for the Study Period of 2019-2032, Estimates DelveInsight - PR NewswireMarch 9, 2022 | radio.foxnews.comDr. Nicole Saphier On New Study That Finds Covid May Cause Changes In The Brain - FOX News RadioDecember 7, 2021 | seekingalpha.comPetros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics - Seeking AlphaNovember 16, 2021 | marketscreener.comPETROS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - marketscreener.comAugust 10, 2021 | nasdaq.comNeurotrope, Inc. Common Stock (NTRP)August 5, 2021 | prnewswire.comPrimary Hyperoxaluria Market Size Growth to Shore Up at a Substantial CAGR of 40.40% During the Study Period 2018-30 in the 7MM | DelveInsight - PRNewswireSee More Headlines Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2018Today6/13/2024Next Earnings (Estimated)6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Miscellaneous manufacturing industries Sub-IndustryN/A Current SymbolNASDAQ:NTRP CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,690,000.00 Net Margins-1,123.90% Pretax Margin-1,123.90% Return on Equity-180.93% Return on Assets-148.77% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio0.76 Sales & Book Value Annual Sales$630,000.00 Price / Sales2.41 Cash FlowN/A Price / Cash FlowN/A Book Value$9.67 per share Price / Book0.20Miscellaneous Outstanding Shares780,000Free Float679,000Market Cap$1.52 million OptionableNo Data Beta1.65 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Charles S. Ryan J.D. (Age 56)Ph.D., Chief Exec. Officer and Director Comp: $850.21kDr. Daniel L. Alkon (Age 78)Pres & Chief Science Officer Comp: $275kMr. Robert Weinstein (Age 60)Chief Financial Officer, Exec. VP, Sec. and Treasurer Comp: $423.82kMr. Jeffrey BenisonDirector of Corp. CommunicationsDr. Alan J. Tuchman (Age 73)Acting Chief Medical Officer Key CompetitorsJE CleantechNASDAQ:JCSEHepion PharmaceuticalsNASDAQ:HEPAGuardion Health SciencesNASDAQ:GHSIAzurRx BioPharmaNASDAQ:AZRXAcasti PharmaNASDAQ:ACSTView All Competitors NTRP Stock Analysis - Frequently Asked Questions When is Neurotrope's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 17th 2024. View our NTRP earnings forecast. How were Neurotrope's earnings last quarter? Neurotrope, Inc. (NASDAQ:NTRP) posted its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05. Neurotrope had a negative net margin of 1,123.90% and a negative trailing twelve-month return on equity of 180.93%. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Alibaba Group (BABA), Zevra Therapeutics (KMPH), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Vistagen Therapeutics (VTGN), Intel (INTC). This page (NASDAQ:NTRP) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.